Department of Pediatric Hematology and Oncology, Royal Marsden Hospital NHS Foundation Trust, London, UK.
Department of Pediatric Hematology and Oncology, Hannover Medical School, Hannover, Germany.
Br J Haematol. 2021 Jun;193(6):1178-1184. doi: 10.1111/bjh.17398. Epub 2021 Mar 25.
Primary central nervous system (CNS) post-transplant lymphoproliferative disorder (PTLD) in childhood is rare. Twenty-five patients were retrieved from nine European Intergroup for Childhood Non-Hodgkin's Lymphoma and/or international Berlin-Frankfurt-Münster Study Group members. Types of allografts included kidney (n = 11), liver (n = 4), heart (n = 5), bowel (n = 1) and haematopoietic stem cells (n = 4). Eighteen were male, 16 ≥ 10 years old, 21 had monomorphic disease and 24 solid intracranial tumour masses. Four-year event-free and overall survival rates were 50% ± 10% and 74% ± 9% respectively. This report represents the largest paediatric series of CNS PTLD reported to date, showing favourable survival odds following systemic and intrathecal chemotherapy and rituximab administration.
儿童原发性中枢神经系统(CNS)移植后淋巴组织增生性疾病(PTLD)较为罕见。本研究从 9 个欧洲儿童非霍奇金淋巴瘤分组和/或国际柏林-法兰克福-明斯特研究分组中检索到 25 例患者。同种异体移植物类型包括肾脏(n=11)、肝脏(n=4)、心脏(n=5)、肠道(n=1)和造血干细胞(n=4)。18 例为男性,16 例≥10 岁,21 例为单形性疾病,24 例为实体颅内肿瘤。4 年无事件生存率和总生存率分别为 50%±10%和 74%±9%。本报告代表了迄今为止报告的最大的儿童 CNS PTLD 系列,显示出在接受全身和鞘内化疗以及利妥昔单抗治疗后具有良好的生存优势。